Telemonitoring in patients with chronic heart failure and moderate depressed symptoms: results of the <scp>Telemedical Interventional Monitoring in Heart Failure</scp> (<scp>TIM‐HF</scp>) study

Telemedicine (TM) is potentially a way of escalating heart failure (HF) multidisciplinary integrated care. Despite the initial efforts to implement TM in HF management, we are still at an early stage of its implementation. The coronavirus disease 2019 pandemic led to an increased utilisation of TM. This tendency will probably remain after the resolution of this threat. Face-to-face medical interventions are gradually transitioning to the virtual setting by using TM. TM can improve healthcare accessibility and overcome geographic inequalities. It promotes healthcare system efficiency gains, and improves patient self-management and empowerment. In cooperation with human intervention, artificial intelligence can enhance TM by helping to deal with the complexities of multicomorbidity management in HF, and will play a relevant role towards a personalised HF patient approach. Artificial intelligence-powered/telemedical/heart team/multidisciplinary integrated care may be the next step of HF management. In this review, the authors analyse TM trends in the management of HF patients and foresee its future challenges within the scope of HF multidisciplinary integrated care.

show abstract

“…[ 2 , 18 , 19 ] TM has also been shown to improve depressive symptoms and quality of life in HF patients with moderate depression. [ 20 ]…”

Section: Telemedicine In Heart Failure: Remote Patient Managementmentioning

confidence: 99%

“…The need for HF patient empowerment and proximity care, which can be addressed by TM, and will become a relevant tool in promoting a personalised medicine. [ 2 – 4 , 9 , 19 , 20 , 40 ]…”

Section: The Digital Transformation Of Heart Failure Carementioning

confidence: 99%

The Future of Telemedicine in the Management of Heart Failure Patients

et al. 2021

View full text Add to dashboard Cite

show abstract

“…39 TIM-HF2 (Telemedical Interventional Management in Heart Failure II study) trial showed a positive impact of telemedicine on unplanned CV hospitalization and mortality. [234][235][236] The HOME-HF study was designed to assess the feasibility and efficacy of BNP home measurement in reduction of HF-related events. It was early interrupted because of slow enrolment, low event rate, and the need of standardize BNP spontaneous fluctuation.…”

Section: Telemedicine and Disease Managementmentioning

confidence: 99%

“…Home telemonitoring is a useful tool for the management of HF patients 39 . TIM‐HF2 (Telemedical Interventional Management in Heart Failure II study) trial showed a positive impact of telemedicine on unplanned CV hospitalization and mortality 234–236 . The HOME‐HF study was designed to assess the feasibility and efficacy of BNP home measurement in reduction of HF‐related events.…”

Section: Devicesmentioning

confidence: 99%

Heart failure in the last year: progress and perspective

et al. 2020

View full text Add to dashboard Cite

Research about heart failure (HF) has made major progress in the last years. We give here an update on the most recent findings. Landmark trials have established new treatments for HF with reduced ejection fraction. Sacubitril/valsartan was superior to enalapril in PARADIGM‐HF trial, and its initiation during hospitalization for acute HF or early after discharge can now be considered. More recently, new therapeutic pathways have been developed. In the DAPA‐HF and EMPEROR‐Reduced trials, dapagliflozin and empagliflozin reduced the risk of the primary composite endpoint, compared with placebo [hazard ratio (HR) 0.74; 95% confidence interval (CI) 0.65–0.85; P < 0.001 and HR 0.75; 95% CI 0.65–0.86; P < 0.001, respectively]. Second, vericiguat, an oral soluble guanylate cyclase stimulator, reduced the composite endpoint of cardiovascular death or HF hospitalization vs. placebo (HR 0.90; 95% CI 0.82–0.98; P = 0.02). On the other hand, both the diagnosis and treatment of HF with preserved ejection fraction, as well as management of advanced HF and acute HF, remain challenging. A better phenotyping of patients with HF would be helpful for prognostic stratification and treatment selection. Further aspects, such as the use of devices, treatment of arrhythmias, and percutaneous treatment of valvular heart disease in patients with HF, are also discussed and reviewed in this article.

show abstract

“…patient self‐managed testing, wearable devices, technologies integrated into pacemakers and defibrillators) 26 . In a pre‐specified analysis of the TIM‐HF (Telemedical Interventional Monitoring in Heart Failure) trial, telemedicine significantly improved symptoms of depression and quality of life over a period of 12 months 27 …”

Section: Disease Managementmentioning

confidence: 99%